



Therapy of Diabetes/HIV

Simplified Therapy of Diabetes/HIV

BROOKLYN, NY, KING'S COUNTY, USA, December 17, 2015 /EINPresswire.com/ -- Problem: Type 2 Diabetes and [HIV/AIDS](#) are the major cause of rise in healthcare cost. Currently, each disease is treated separately and require complex management.

Statistics: In U.S. the National Healthcare Expenditure (NHE) is projected to hit \$3.207 trillion this year averaging \$ 10,000.00 per person. According to Center for Disease Control and Prevention (CDC), there are 1.2 Million patients with HIV in USA in 2012 above age 13 years. Meanwhile, diabetes number continue to escalate. There are now 29 million people with diabetes and 86 million patients with prediabetes.

Hypothesis: "Inflammation hypothesis" is gaining ground as the major cause of diabetes. Accelerated incidence of Diabetes in the presence of HIV/AIDS is a specific example to support this hypothesis. Standard therapies, don't target inflammation or its underlying cause in HIV/AIDS as well as in diabetes. This is driving up the cost of medical care. Advances in HIV therapies led to the global gains in drastically reducing mortality of millions of infected HIV people. They are living longer. HIV patients are at 11% or more at risk of developing Type 2 Diabetes with better antiviral drugs and weight gain.

Technology Advances: Endocrine Technology, L.L.C. detailed at www.etbondusa.com details a new patent application targeting inflammation as a common molecular target in HIV/AIDS and Type 2 diabetes.

Therapeutic Application: Endocrine Technology, L.L.C. has established an executive clinic detailed at www.etdiabetescenter.com that simplifies therapy of Type 2 diabetes using data analytic and latest advances.

Endocrine Technology, L.L.C. encourage and welcome patients with diabetes and HIV/AIDS to register at website: www.etdiabetescenter.com for the futuristic clinical trials and to obtain state of the art approved therapies.

Kumar Shah
Endocrine Technology, LLC
718-222-1065
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.